» Articles » PMID: 6700714

Transforming Ras Genes from Human Melanoma: a Manifestation of Tumour Heterogeneity?

Overview
Journal Nature
Specialty Science
Date 1984 Mar 1
PMID 6700714
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Variability in the phenotype of cells comprising individual tumours is a striking feature of animal and human cancer and is generally referred to as tumour heterogeneity. Studies of clonally derived cell populations from tumours that originated presumably from a single transformed cell have shown that tumours are made up of cells that differ in a variety of traits, including drug resistance, antigen expression and metastatic potential. The origin and maintenance of tumour heterogeneity are unclear, but mutational and epigenetic mechanisms are thought to be involved. Here we report the results of a search for transforming genes in human melanoma which have raised the possibility that ras gene activation follows the same variable pattern as other traits involved in tumour heterogeneity. DNA from 4 of 30 melanoma cell lines yielded transforming ras genes in the NIH/3T3 assay. Of five cell lines originating from separate metastatic deposits of a single patient, only one contained activated ras, indicating heterogeneity in ras activation in this case and suggesting that ras activation was not involved in tumour initiation or maintenance in this patient.

Citing Articles

Twenty years of research in melanoma therapy-From "nothing works" to cures: A personal account.

Herlyn M, Villanueva J Pigment Cell Melanoma Res. 2023; 36(6):583-587.

PMID: 37726985 PMC: 11187729. DOI: 10.1111/pcmr.13133.


Targeting Mutations in Advanced Melanoma.

Phadke M, Smalley K J Clin Oncol. 2023; 41(14):2661-2664.

PMID: 36947724 PMC: 10414701. DOI: 10.1200/JCO.23.00205.


Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.

Zob D, Augustin I, Caba L, Panzaru M, Popa S, Popa A Int J Mol Sci. 2023; 24(1).

PMID: 36614156 PMC: 9821083. DOI: 10.3390/ijms24010716.


Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.

Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q J Cancer Res Clin Oncol. 2022; 149(2):701-708.

PMID: 36454283 DOI: 10.1007/s00432-022-04377-4.


BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS-mutated melanomas to targeted therapy.

McGrail K, Granado-Martinez P, Esteve-Puig R, Garcia-Ortega S, Ding Y, Sanchez-Redondo S Nat Commun. 2022; 13(1):7113.

PMID: 36402789 PMC: 9675737. DOI: 10.1038/s41467-022-34907-0.